RAS and BRAF in metastatic colorectal cancer management - sprookjes - yvandenbroek - TriplyDB

RAS and BRAF in metastatic colorectal cancer management

RAS and BRAF in metastatic colorectal cancer management

http://www.wikidata.org/entity/Q28074175

about

MicroRNAs in the etiology of colorectal cancer: pathways and clinical implications.Next-Generation Sequencing to Guide Treatment of Advanced Melanoma.A single institute retrospective trial of concurrent chemotherapy with SIR-Spheres® versus SIR-Spheres® alone in chemotherapy-resistant colorectal cancer liver metastases.Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits.Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab.A Network Pharmacology Approach to Uncover the Multiple Mechanisms of Hedyotis diffusa Willd. on Colorectal Cancer.BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report.Report from the 19th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29-30 September 2017

P2860

Q37731180-0A4C2653-8290-4275-9456-8D8CBBCCA95D Q38754313-06984A2D-4BF0-421A-9D6F-00458EDAAAB1 Q41598591-B7C69656-AD63-4DBE-99B5-0F9B4F4BD22E Q42361474-ED2BE20D-6CB5-42D8-9DE5-89603AF9AA64 Q45740557-DD1AFF57-F247-4100-9806-4DF1F82DF611 Q54990524-8C4EBFAE-D0D5-4BC4-B9EB-CB26BD88A408 Q55090775-4549F34E-AFED-483B-9257-8392B6375ADB Q58783248-8920EBCD-E4E1-4AE3-A7C9-36BACB03B75F

P2860

RAS and BRAF in metastatic colorectal cancer management

http://www.wikidata.org/entity/Q28074175

description

2016 nî lūn-bûn

@nan

2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

RAS and BRAF in metastatic colorectal cancer management

@ast

RAS and BRAF in metastatic colorectal cancer management

@en

RAS and BRAF in metastatic colorectal cancer management

@nl

type

label

RAS and BRAF in metastatic colorectal cancer management

@ast

RAS and BRAF in metastatic colorectal cancer management

@en

RAS and BRAF in metastatic colorectal cancer management

@nl

prefLabel

RAS and BRAF in metastatic colorectal cancer management

@ast

RAS and BRAF in metastatic colorectal cancer management

@en

RAS and BRAF in metastatic colorectal cancer management

@nl

P1433

Q28074175-B4ADB03B-87FD-4BD5-AF21-2060E04C2479

P1476

Q28074175-B6B46D12-ECA0-4AAE-AE82-274F4FC91D88

P2093

Q28074175-75C1C9C9-E706-4CAF-AF37-BDAAA8458EFB

Q28074175-7E92E92B-EC62-4E3D-B8AD-B6BDEA9672C6

Q28074175-D1C0D91A-64F2-4DAE-97AD-1C74323CCA6E

P2860

Q28074175-0367BBBB-0B3D-4AE2-8927-AD4C5BCA2522

Q28074175-05C6073D-DE9F-4326-A768-B914090B24E4

Q28074175-0939295A-1721-4F7D-9280-31AC0AF40A47

Q28074175-0C8F2134-A7B2-4C6F-BFD6-521C9B5520FC

Q28074175-0E879793-286B-44CA-B328-CD57BB854CED

Q28074175-1099FF32-4F23-4556-815B-ABAFFA30C110

Q28074175-10E3FACB-ABD4-4988-8CCF-88D1625035D2

Q28074175-16E14565-3D5D-45D9-B844-5B27C7D462BC

Q28074175-186A9A29-20B4-4187-9392-B21FBD473B0C

Q28074175-19DCCFB7-E7B0-4187-BAEB-632598625B07

P304

Q28074175-4C3D152F-8257-422B-8351-23AC8DEF0A38

P31

Q28074175-3D9258D2-8F52-4AC8-9E28-6E9BAA3EB332

P356

Q28074175-B164460E-C453-4159-81F7-4EDA7C767A3B

P407

Q28074175-08998A17-387A-4661-B4D1-78817F5991AF

P433

Q28074175-7D6C96D8-198C-4A1E-831D-030DDFD2C954

P478

Q28074175-644176CB-6BDE-425B-8C60-0B6D93BE6395

P577

Q28074175-D89925A3-B9E8-4B13-9EA5-9ABC1DDB142C

P698

Q28074175-715C30D8-34BD-4B1F-A361-2F1ECEFE6163

P921

Q28074175-2A7C4F27-97C4-47A9-8F8A-4C8F8C177247

P932

Q28074175-9638190E-4B07-4EA8-9FC5-4F3034B0F7A6

P356

P1433

Journal of gastrointestinal oncology

P1476

RAS and BRAF in metastatic colorectal cancer management

@en

P2093

Jun Gong

http://www.w3.org/2001/XMLSchema#string

Marwan Fakih

http://www.w3.org/2001/XMLSchema#string

May Cho

http://www.w3.org/2001/XMLSchema#string

P2860

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Comprehensive molecular characterization of human colon and rectal cancer

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Cetuximab for the treatment of colorectal cancer.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

P304

687-704

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/JGO.2016.06.12

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27747083

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5056249

http://www.w3.org/2001/XMLSchema#string